<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01924013</url>
  </required_header>
  <id_info>
    <org_study_id>1000039072</org_study_id>
    <nct_id>NCT01924013</nct_id>
  </id_info>
  <brief_title>Maternal Vitamin D for Infant Growth (MDIG) Trial</brief_title>
  <acronym>MDIG</acronym>
  <official_title>Randomized Placebo-controlled Trial of Maternal Vitamin D Supplementation During Pregnancy and Lactation to Improve Infant Linear Growth in Dhaka, Bangladesh.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Centre for Diarrhoeal Disease Research, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shimantik</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aims of this study are: 1) to determine whether maternal prenatal vitamin D3
      supplementation (4200 IU/week, 16,800 IU/week, or 28,000 IU/week) versus placebo increases or
      decreases infant length at 1 year of age, and 2) to determine whether maternal postpartum
      vitamin D3 supplementation (28,000 IU/week) versus placebo increases or decreases length at 1
      year of age among infants born to women who received vitamin D 28,000 U/week during
      pregnancy. Infants enrolled in the study will be followed for 2 years to document the
      persistence of any observed effects measured at 1 year of age. This study aims to enroll 1300
      pregnant women in the 2nd trimester at a maternity hospital in Dhaka. Participants will be
      randomized to one of three doses of vitamin D3 (4200 IU/week, 16,800 IU/week, or 28,000
      IU/week) or placebo throughout pregnancy. Women in the 28,000 IU/week group will be
      additionally randomized to either placebo or a continuation of 28,000 IU/week for 6 months
      postpartum. In addition to linear length, the trial will include analyses of inflammatory and
      hormonal determinants of infant growth, epigenetic phenomena that affect vitamin D
      metabolism, and diarrheal and respiratory morbidity in the infants.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infant Length-for-Age Z-Scores with Prenatal Supplementation</measure>
    <time_frame>1 year of age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Infant Length-for-Age Z-Scores with Postpartum Supplementation</measure>
    <time_frame>1 year of age</time_frame>
    <description>A separate analysis will be performed to assess the effect of continuation of 28,000 IU/week postpartum supplementation versus placebo (postpartum) among participants randomized to 28,000 IU/week prenatal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum calcium</measure>
    <time_frame>17 weeks gestation to birth (prenatal) and over 2 years postpartum</time_frame>
    <description>Maternal serum calcium will be measured during pregnancy as a primary biochemical safety parameter and post partum.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Stunting (LAZ &lt; -2 SD below the median) at 1 and 2 years of age.</measure>
    <time_frame>1-2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Attained length and LAZ at 2 years of age.</measure>
    <time_frame>2 years postnatal</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Birth weight, low birth weight %, small-for-gestational age %</measure>
    <time_frame>Birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Preterm birth %</measure>
    <time_frame>Birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stillbirth %</measure>
    <time_frame>17 weeks gestation to 39 weeks</time_frame>
    <description>Prenatal period</description>
  </other_outcome>
  <other_outcome>
    <measure>Maternal, perinatal, neonatal and infant severe morbidity and mortality</measure>
    <time_frame>From 17 weeks gestation to 6 months postpartum</time_frame>
    <description>During intervention phase (prenatal and first 6 months postpartum)</description>
  </other_outcome>
  <other_outcome>
    <measure>Infant acute respiratory infections and diarrhea</measure>
    <time_frame>6 months postpartum</time_frame>
    <description>first 6 months postnatal</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarker concentrations (specific hormones, nutrients, environmental contaminants, and inflammatory markers potentially involved in the mediation or modification of the effect of vitamin D on infant stunting).</measure>
    <time_frame>17 weeks gestation to 2 years postpartum</time_frame>
    <description>Prenatal and first 2 years postnatal</description>
  </other_outcome>
  <other_outcome>
    <measure>Epigenetic patterns of genes involved in vitamin D metabolism.</measure>
    <time_frame>Birth</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1300</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Prenatal Period 0 IU; Postpartum Period 0 IU (placebo)
Overall:The Prenatal Period will start at enrolment (17-24 weeks gestation) and last until delivery. The Postpartum Period will last from delivery until 6 months postpartum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prenatal Period 4,200 IU/week of vitamin D3 (=600 IU/d); Postpartum Period 0 IU/week (placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prenatal Period 16,800 IU/week of vitamin D3 (=2,400 IU/d); Postpartum Period 0 IU/week (placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prenatal Period 28,000 IU/week of vitamin D3 (=4,000 IU/d); Postpartum Period 0 IU/week (placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prenatal Period 28,000 IU/week of vitamin D3 (=4,000 IU/d); Postpartum Period 28,000 IU/week(=4,000 IU/d)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 (cholecalciferol)</intervention_name>
    <description>The intervention is an oral tablet containing vitamin D3 (cholecalciferol). This vitamin D supplement will be provided in the form of small tablets (approximately 10 mm diameter) and will be custom- manufactured by Toronto Institute for Pharmaceutical Technology (TIPT) in Toronto, Ontario, Canada. Each weekly dose will consist of a single tablet. Across trial groups, the tablets will only vary with respect to the vitamin D3 dose, as described above.</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This product will be identical in appearance, taste and texture to the experimental formulation but will not include any vitamin D3.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18 years and above.

          -  Gestational age of 17 to 24 completed weeks estimated based on recalled last menstrual
             period (LMP) and/or ultrasound.

          -  Intends to permanently reside in the trial catchment area for at least 18 months.

        Exclusion Criteria:

          -  History of medical conditions that may predispose the participant to vitamin D
             sensitivity, altered vitamin D metabolism and/or hypercalcemia, or history of renal
             calculi.

          -  High-risk pregnancy based on one or more of the following findings by point-of-care
             testing:

               -  Severe anemia: hemoglobin &lt;70 g/L assessed by Hemocue

               -  Moderate-severe proteinuria: ≥ 300 mg/dl (3+ or 4+) based on urine dipstick

               -  Hypertension: systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure
                  ≥90 mm Hg

          -  Multiple gestation, major congenital anomaly, or severe oligohydramnios based on
             maternal history and/or ultrasound.

          -  Unwillingness to stop taking non-study vitamin D or calcium supplements or a
             multivitamin with calcium and/or vitamin D.

          -  Currently prescribed vitamin D supplements as part of a physician's treatment plan for
             vitamin D deficiency.

          -  Previous participation in the same study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Roth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>International Centre for Diarrhoeal Disease Research, Bangladesh</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2013</study_first_submitted>
  <study_first_submitted_qc>August 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2013</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Daniel Roth</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Infant Growth</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Bangladesh</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

